Recent advances and challenges of cellular immunotherapies in lung cancer treatment
Abstract Lung cancer is a major malignant tumor with high morbidity and fatality rates. For many years, traditional treatments for lung cancer have struggled to achieve a favorable outlook and prognosis. It is crucial to identify and innovate novel clinical therapeutic strategies and techniques to p...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Experimental Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40164-025-00679-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849344013432258560 |
|---|---|
| author | Chengfei Yang Yue Liu Ziqi Huang Sijin Liu Xi Zhang Quanxing Liu Jigang Dai |
| author_facet | Chengfei Yang Yue Liu Ziqi Huang Sijin Liu Xi Zhang Quanxing Liu Jigang Dai |
| author_sort | Chengfei Yang |
| collection | DOAJ |
| description | Abstract Lung cancer is a major malignant tumor with high morbidity and fatality rates. For many years, traditional treatments for lung cancer have struggled to achieve a favorable outlook and prognosis. It is crucial to identify and innovate novel clinical therapeutic strategies and techniques to prevent tumor progression and prolong the survival time of patients with lung cancer. Cellular immunotherapies have revolutionized the treatment of malignant tumors and have been gradually applied in clinical practice. CAR-T therapy is the best-known cellular therapy and has achieved remarkable clinical outcomes in patients with hematological malignancies, but its effect on patients with lung cancer and other solid tumors is not satisfactory, partly because of the heterogeneity and complexity of lung cancers and the sterile TMEs. To further improve the clinical effect, multiple approaches and strategies have been adopted, including discovering new tumor antigen targets, improving safety, enhancing cytotoxicity, and increasing durability. Moreover, other cell-based immunotherapies have also showed great potential for the treatment of lung cancer, including TCR-T cells, TILs, CIK cells, NK cells, macrophages, and dendritic cells, which enriched the number of treatment choices for patients with lung cancer. In summary, the present article summarizes and highlights recent advances and challenges in the use of cellular immunotherapies for the treatment of lung cancer, which might stimulate new ideas for the further development of cellular immunotherapies. |
| format | Article |
| id | doaj-art-8465ba8f6c7d4f7dab74ee6b2fba7bfc |
| institution | Kabale University |
| issn | 2162-3619 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Experimental Hematology & Oncology |
| spelling | doaj-art-8465ba8f6c7d4f7dab74ee6b2fba7bfc2025-08-20T03:42:48ZengBMCExperimental Hematology & Oncology2162-36192025-07-0114112710.1186/s40164-025-00679-8Recent advances and challenges of cellular immunotherapies in lung cancer treatmentChengfei Yang0Yue Liu1Ziqi Huang2Sijin Liu3Xi Zhang4Quanxing Liu5Jigang Dai6Department of Thoracic Surgery, Xinqiao Hospital, Army Medical University (Third Military Medical University)Medical Center of Hematology, State Key Laboratory of Trauma and Chemical Poisoning, Chongqing Key Laboratory of Hematology and Microenvironment, Xinqiao Hospital of Army Medical UniversityDepartment of Thoracic Surgery, Xinqiao Hospital, Army Medical University (Third Military Medical University)Department of Thoracic Surgery, Xinqiao Hospital, Army Medical University (Third Military Medical University)Medical Center of Hematology, State Key Laboratory of Trauma and Chemical Poisoning, Chongqing Key Laboratory of Hematology and Microenvironment, Xinqiao Hospital of Army Medical UniversityDepartment of Thoracic Surgery, Xinqiao Hospital, Army Medical University (Third Military Medical University)Department of Thoracic Surgery, Xinqiao Hospital, Army Medical University (Third Military Medical University)Abstract Lung cancer is a major malignant tumor with high morbidity and fatality rates. For many years, traditional treatments for lung cancer have struggled to achieve a favorable outlook and prognosis. It is crucial to identify and innovate novel clinical therapeutic strategies and techniques to prevent tumor progression and prolong the survival time of patients with lung cancer. Cellular immunotherapies have revolutionized the treatment of malignant tumors and have been gradually applied in clinical practice. CAR-T therapy is the best-known cellular therapy and has achieved remarkable clinical outcomes in patients with hematological malignancies, but its effect on patients with lung cancer and other solid tumors is not satisfactory, partly because of the heterogeneity and complexity of lung cancers and the sterile TMEs. To further improve the clinical effect, multiple approaches and strategies have been adopted, including discovering new tumor antigen targets, improving safety, enhancing cytotoxicity, and increasing durability. Moreover, other cell-based immunotherapies have also showed great potential for the treatment of lung cancer, including TCR-T cells, TILs, CIK cells, NK cells, macrophages, and dendritic cells, which enriched the number of treatment choices for patients with lung cancer. In summary, the present article summarizes and highlights recent advances and challenges in the use of cellular immunotherapies for the treatment of lung cancer, which might stimulate new ideas for the further development of cellular immunotherapies.https://doi.org/10.1186/s40164-025-00679-8Cellular immunotherapyLung cancerCAR-T therapyAntigen targetsTumor microenvironmentCombination immunotherapy strategy |
| spellingShingle | Chengfei Yang Yue Liu Ziqi Huang Sijin Liu Xi Zhang Quanxing Liu Jigang Dai Recent advances and challenges of cellular immunotherapies in lung cancer treatment Experimental Hematology & Oncology Cellular immunotherapy Lung cancer CAR-T therapy Antigen targets Tumor microenvironment Combination immunotherapy strategy |
| title | Recent advances and challenges of cellular immunotherapies in lung cancer treatment |
| title_full | Recent advances and challenges of cellular immunotherapies in lung cancer treatment |
| title_fullStr | Recent advances and challenges of cellular immunotherapies in lung cancer treatment |
| title_full_unstemmed | Recent advances and challenges of cellular immunotherapies in lung cancer treatment |
| title_short | Recent advances and challenges of cellular immunotherapies in lung cancer treatment |
| title_sort | recent advances and challenges of cellular immunotherapies in lung cancer treatment |
| topic | Cellular immunotherapy Lung cancer CAR-T therapy Antigen targets Tumor microenvironment Combination immunotherapy strategy |
| url | https://doi.org/10.1186/s40164-025-00679-8 |
| work_keys_str_mv | AT chengfeiyang recentadvancesandchallengesofcellularimmunotherapiesinlungcancertreatment AT yueliu recentadvancesandchallengesofcellularimmunotherapiesinlungcancertreatment AT ziqihuang recentadvancesandchallengesofcellularimmunotherapiesinlungcancertreatment AT sijinliu recentadvancesandchallengesofcellularimmunotherapiesinlungcancertreatment AT xizhang recentadvancesandchallengesofcellularimmunotherapiesinlungcancertreatment AT quanxingliu recentadvancesandchallengesofcellularimmunotherapiesinlungcancertreatment AT jigangdai recentadvancesandchallengesofcellularimmunotherapiesinlungcancertreatment |